Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation

Abstract EN

Prostate cancer is the second most common cancer in men worldwide.

This study focused to clarify the roles of Metadherin (MTDH) and miR-342-3p in prostate cancer.

We identified that MTDH was upregulated and miR-342-3p was down-regulated in the prostate tissues, and there is an inverse correlation between MTDH and miR-342-3p.

Functional studies revealed that miR-342-3p directly targets MTDH via binding to the 30 untranslated regions (UTRs) in the prostate cancer cells.

Moreover, we also found MTDH overexpression in DU145 and PC3 cells inhibited apoptosis.

Subsequently, miR-342-3p has been revealed to reverse the MTDH effect on the cellular apoptosis in the further studies.

Our results indicate that MTDH repress apoptosis of prostate cancer in vitro and provides a new strategy for human prostate cancer therapy in the future.